10-K: Bioxytran Reports 2025 Financials, Advances Drug Development

Bioxytran, Inc. filed its annual report for the year ended December 31, 2025, detailing progress in its pharmaceutical development pipeline and financial status.

Summary

• Bioxytran, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for viral infections, hypoxia, and degenerative diseases.
• The company's lead candidates include ProLectin-M for COVID-19 and BXT-25, an acellular oxygen carrier for stroke treatment.
• For the year ended December 31, 2025, Bioxytran reported a net loss of $2,123,077, an improvement from the $2,366,681 net loss in 2024.
• The company's cash position improved significantly, ending the year at $509,914, up from $5,154 in the prior year, primarily due to financing activities.
• Bioxytran is actively seeking additional capital, estimating a need of $2-3 million in 2026 to fund its ongoing development and operations.
• The company's stock is quoted on the OTCQB market, and it is classified as a smaller reporting company.
• Key management includes CEO and Chairman David Platt, Ph.D., and CFO Ola Soderquist.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the company's continued losses, substantial accumulated deficit, and ongoing going concern issues, despite some progress in drug development and financing.

Positives

• Net loss decreased to $2,123,077 in 2025 from $2,366,681 in 2024.
• Cash balance increased substantially to $509,914 as of December 31, 2025, from $5,154 at the end of 2024.
• The company's ProLectin-M showed positive results in Phase 2 trials for COVID-19, with a 100% response rate by day 7.
• FDA approval for the PROTECT IND for ProLectin-M was obtained on August 21, 2023.
• The company has a strong patent portfolio and experienced management team.
• The company has a clear strategy to license its drug candidates to larger pharmaceutical companies.

Negatives

• The company has an accumulated deficit of $21,044,246 as of December 31, 2025.
• Net working capital is negative at $(2,736,430) as of December 31, 2025.
• The company has not yet generated significant revenue and is dependent on future financing.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's stock is traded on the OTCQB, indicating limited liquidity and higher risk.
• Material weaknesses in internal control over financial reporting were identified, primarily due to a lack of segregation of duties.

Risks

• The company expects to incur losses for the foreseeable future and may never achieve profitability.
• Additional financing is required to implement the business plan, and such financing may not be available on favorable terms or at all.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to drug candidates.
• Product development involves lengthy, expensive processes with uncertain outcomes, and the company may incur additional costs or delays.
• The company may be unable to commercialize its drug candidates.
• Success depends on retaining key executives and attracting qualified personnel.
• The company's competitive position relies on intellectual property protection, and it may face expensive patent litigation.
• The market for its products is rapidly changing and competitive.
• The company has a material weakness in internal controls over financial reporting due to a lack of segregation of duties.

Future Outlook

The company requires additional financing of approximately $2-3 million in 2026 to sustain operations and complete development activities. Without sufficient capital, the company may need to scale back its business plan or curtail operations. The Phase 3 trial for ProLectin-M is projected to start in the third quarter of 2026, contingent on adequate funding.

Management Comments

• The company's management believes that raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to drug candidates.
• Management believes that its regulatory development pathway is a standard generic pathway approval for a drug.
• Management believes that its drug development leadership team provides a significant competitive advantage.
• Management believes that the small size of the accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit of such remediation.

Industry Context

StockSavvy.ai notes that Bioxytran operates in the highly competitive and capital-intensive biotechnology sector, focusing on novel drug development for viral infections and hypoxia. The company's reliance on carbohydrate drug design and galectin inhibition places it in a niche area, with potential for significant impact if its platform technologies prove successful. The company's progress with ProLectin-M in COVID-19 trials and BXT-25 for stroke treatment aligns with broader industry trends of seeking innovative solutions for unmet medical needs.

Comparison to Industry Standards

• The company's R&D expenses of $454,000 for 2025 are significantly lower than those of established pharmaceutical companies, reflecting its early-stage development status.
• The net loss of $2,123,077 in 2025 is typical for pre-revenue biotechnology companies investing heavily in research and development.
• The company's reliance on external financing through private placements and potential public offerings is a common strategy for early-stage biotech firms to fund their lengthy and expensive drug development cycles.
• The company's stated strategy to license out its developed drugs to larger pharmaceutical companies is a standard exit or commercialization strategy in the biotech industry.

Corporate Governance

Legal Proceedings

• The company terminated an officer for cause on December 29, 2025, who has contested the allegations and filed a worker rights complaint, which the company disputes.

Related Party Transactions

• Acquisition of NDPD Pharma, Inc. from affiliates, involving issuance of Bioxytran Preferred and Common Stock.
• License agreement with an affiliated company for a medical device, where company officers hold a majority interest.
• Significant amounts in accounts payable and loans from affiliates.
• Stock-based compensation to affiliates for services rendered.
• Payroll and advanced expenses due to affiliates.

Stakeholder Impact

• Shareholders may experience dilution due to future capital raises and potential conversion of convertible notes.
• The company's ability to continue as a going concern poses a significant risk to all stakeholders.
• Employees' job security may be impacted by the company's financial situation and need for restructuring.
• Creditors and suppliers may face delays in payment due to the company's liquidity challenges.

Next Steps

• Advance ProLectin-M towards Phase 3 application.
• Begin pre-clinical studies for BXT-25 and apply to the FDA for approval.
• Seek additional capital through private placements and public offerings.
• Continue to develop novel formulations and leverage development partnerships.
• Assemble scientific and medical advisory boards.

Key Dates

Recommendation

The company exhibits significant financial distress, including a going concern warning, substantial accumulated deficit, and negative working capital. While there is progress in drug development, the high risk associated with financing needs and the lack of revenue generation make it a speculative investment. The limited market for its OTCQB-traded stock further exacerbates the risk for investors.

Keywords

Bioxytran, 10-K, Pharmaceutical, Drug Development, COVID-19, ProLectin-M, BXT-25, Hypoxia, Stroke Treatment, Galectin Inhibitors, Clinical Trials, FDA, SEC Filing, Biotechnology